Meta-analysis of 55 cohorts (4630 patients with multiple myeloma) after BCMA CAR-T: pooled non-ICANS neurological toxicity was 0.81% (95% CI 0.37-1.77%), higher with cilta-cel than ide-cel (4.6% vs 0.5%); cranial nerve palsies were commonest.
Meta-analysisn = 4,630
van Besien et al. Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma